Morgan Stanley upgraded shares of Hikma Pharmaceuticals (OTCMKTS:HKMPF) from an equal weight rating to an overweight rating in a research report sent to investors on Tuesday morning, The Fly reports.
Several other research analysts also recently issued reports on HKMPF. Citigroup upgraded shares of Hikma Pharmaceuticals from a neutral rating to a buy rating in a report on Tuesday, March 10th. Jefferies Financial Group downgraded shares of Hikma Pharmaceuticals from a buy rating to a hold rating in a report on Thursday, April 16th. Barclays reiterated an equal weight rating on shares of Hikma Pharmaceuticals in a report on Tuesday, April 28th. ValuEngine downgraded shares of Hikma Pharmaceuticals from a hold rating to a sell rating in a report on Monday, June 8th. Finally, Goldman Sachs Group downgraded shares of Hikma Pharmaceuticals from a buy rating to a neutral rating in a report on Thursday, April 23rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and three have given a buy rating to the stock. Hikma Pharmaceuticals has an average rating of Hold and an average target price of $32.00.
OTCMKTS HKMPF opened at $27.50 on Tuesday. The business has a fifty day moving average price of $29.46 and a two-hundred day moving average price of $26.51. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.26 and a quick ratio of 0.87. Hikma Pharmaceuticals has a fifty-two week low of $19.75 and a fifty-two week high of $42.00. The stock has a market capitalization of $6.66 billion, a PE ratio of 18.33 and a beta of 0.44.
Hikma Pharmaceuticals PLC develops, manufactures, and markets a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment manufactures, markets, and sells generic injectable products for therapeutic categories, including oncology and anti-viral products to hospitals.
Recommended Story: Basic Economics creates winners and losers
Receive News & Ratings for Hikma Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hikma Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.